The Safety, Tolerability and Biodistribution of a Single Intravenous Administration of Two Zirconium-89 Labelled Vartumabs (F8scFV or C9scFv) in Patients with Solid Tumors - a Phase 0, Open Label, PET/CT Molecular Imaging Basket Trial
Latest Information Update: 24 Oct 2024
At a glance
- Drugs Zirconium 89 Labelled Vartumab (Primary)
- Indications Bladder cancer; Carcinoma; Chondrosarcoma; Colon cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Oropharyngeal cancer; Osteosarcoma; Pancreatic cancer; Rectal cancer; Squamous cell cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms VARTUTRACE
- Sponsors VAR2 Pharmaceuticals
- 24 Oct 2024 New trial record
- 30 Sep 2024 According to VAR2 Pharmaceuticals media release, company has received regulatory approval for their first-in-human Phase 0 clinical trial.The study will be conducted in the Netherlands and patient recruitment will start next month.